3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
6
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Prostatic Neoplasms
24
Carcinoma, Renal Cell
11
Kidney Neoplasms
8
Neoplasm Metastasis
5
Lung Neoplasms
5
Colorectal Neoplasms
5
Colonic Neoplasms
5
Wilms Tumor
4
Pancreatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Urinary Bladder Neoplasms
3
Testicular Neoplasms
3
Rectal Neoplasms
3
Breast Neoplasms
3
Testicular Germ Cell Tumor
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Melanoma
2
Liver Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Medullary
2
Interventions
pembrolizumab
33
Nivolumab
15
atezolizumab
9
Cyclophosphamide
7
Paclitaxel
6
Ipilimumab
6
spartalizumab
5
fludarabine
5
Docetaxel
5
durvalumab
4
avelumab
4
Immune Checkpoint Inhibitors
4
Carboplatin
4
olaparib
3
cemiplimab
3
cabozantinib
3
Specimen Handling
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Interleukin-2
3
Gemcitabine
3
Fluorouracil
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
sacituzumab govitecan
2
obinutuzumab
2
lenvatinib
2
epacadostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
sargramostim
×
Genitourinary
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled